Key result
Oral flecainide acetate successfully achieved cardioversion in a fetus with supraventricular tachycardia and hydrops fetalis, with complete normalization of venous returns.
Case Report (n=1)
Oral flecainide acetate successfully treated fetal supraventricular tachycardia with hydrops fetalis, with venous Doppler analysis proving useful for assessing reversible cardiac dysfunction.
Answers are grounded in this paper and cite their sources.
May support oral flecainide in select fetal SVT with hydrops; leaves open need for prospective validation.
BACKGROUND: The efficacy of flecainide acetate for the treatment of fetal supraventricular tachycardia with hydrops fetalis and changes in venous blood flow patterns in the fetus during treatment are reported. CASE: Oral flecainide administration was started at 30 weeks of gestation. Cardioversion was achieved 6 days after treatment. Sustained abnormal venous Doppler indices were shown and complete normalization of venous returns was observed 6 days after cardioversion. A vigorous male baby was born, and he is now 1 year of age and in good condition with no medication. CONCLUSION: Reversible cardiac dysfunction was observed even after cardioversion in the fetus with supraventricular tachycardia, which could be assessed precisely by venous Doppler analysis.
No takes yet. Share an insight, caveat, or question.
Nakata et al. (2003) conducted a case report in fetal supraventricular tachycardia with hydrops fetalis (n=1). Flecainide acetate was evaluated on Cardioversion and normalization of venous returns. Oral flecainide acetate successfully achieved cardioversion in a fetus with supraventricular tachycardia and hydrops fetalis, with complete normalization of venous returns.
Synapse has enriched 10 related papers. Consider them for comparative context: